Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Sarcoma 1Plasma cell 1

Conditions

Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Kidney Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

pembrolizumab 21Nivolumab 7Docetaxel 7Paclitaxel 5Magnetic Resonance Spectroscopy 5Carboplatin 5Trastuzumab 4Specimen Handling 4Psychiatric Rehabilitation 4Cyclophosphamide 4tisotumab vedotin 3fludarabine 3atezolizumab 3Taxes 3Polymerase Chain Reaction 3Gene Expression Profiling 3Gemcitabine 3Fluorouracil 3Counseling 3Cisplatin 3Albumin-Bound Paclitaxel 3ulixertinib 2poly ICLC 2durvalumab 2belinostat 2X-Rays 2Standard of Care 2Radiotherapy 2Radiation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × poly ICLC × Genitourinary × Clear all
NCT04116320 2025-07-14

AM-003

University of Virginia

Phase 1 Terminated
5 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡